Anzeige
Mehr »
Login
Dienstag, 14.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Das 13-Millionen-Unternehmen mit einer Monster-Entdeckung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
239 Leser
Artikel bewerten:
(1)

Future Market Insights: Pediatric Clinical Trials Market to reach US$ 26.47 Billion by 2032; Phase II Trials to comprise 1/3rd of Global Market Share: FMI Study

Finanznachrichten News

The pediatric clinical trials market is projected to have a global size of $15.8 billion by 2022, with North America's share at 45%. The APAC region will account for 25% while the rest comes from elsewhere around world.

NEWARK, Del., June 16, 2022 /PRNewswire/ -- During the forecast period 2022-2032, the pediatric clinical trials market is expected to grow at a value of 5.3%, according to Future Market Insights. In 2021, this market was predicted to have a global valuation of US$ 15 Billion, and is expected to reach a sum of US$ 26.47 Billion by 2032. The market is going to face increasing demand owing to the increase of pediatric chronic and genetic diseases all across the world.

FMI Logo

The growing need for novel vaccines and biopharmaceuticals to treat infectious diseases such as measles, polio, tuberculosis, rubella, influenza, mumps, whooping cough, malaria, chickenpox, and staphylococcus pharyngitis is expected to drive market growth. At the same time, diabetes is a big worry among today's children. The market is being driven by rising parental awareness of children clinical trials for severe infections and chronic diseases, as well as a large number of CROs doing pediatric research.

Request a Sample PDF @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15017

In 2021, the oncology therapeutic field category had the world's second-largest revenue share. Cancer is the top cause of death in the globe. Cancer cases in children under the age of 19 are anticipated to reach 291,000 by 2040. With the increasing number of pediatric cancer cases worldwide, many hospitals and institutes are focusing on the development of therapeutic drugs, resulting in an increase in the number of pediatric clinical trials globally.

Irrespective of all these growth factors, the global market for pediatric clinical trials can be hindered for some specific reasons. The high rate of pediatric clinical trial discontinuation for a number of reasons is expected to impede growth in the pediatric clinical trials market. Pediatric studies have a high failure rate due to reasons such as patient enrollment. Other concerns include behavioral disorders and trial conduct issues such as inappropriate dosing, formulation difficulty, and informative termination, as well as regulatory challenges and pharmaceutical toxicity during clinical investigations.

Leading Companies Profiled in Pediatric Clinical Trials Market are

  • Synteract
  • ICON Plc.
  • Syneos Health
  • Medpace, Inc
  • PPD Inc.
  • Premier Research
  • LabCorp Drug Development
  • QPS Holding
  • Pfizer Inc.
  • The Emmes Company, LLC
  • IQVIA Inc.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-15017

Key Takeaways from the Market Study

  • In 2022, the global pediatric clinical trials market is estimated to have a global market size of US$ 15.8 Billion
  • The pediatric clinical trials market in North America to acquire 45% of the global market share
  • APAC projected to acquire 25% of the global market share
  • By phase, the phase II clinical trials segment took over 33% of the global pediatric clinical trials market share
  • By study design, the treatment studies for clinical trials acquired 66% of the global market share
  • By therapeutic area, the oncology therapeutic area segment acquired almost 17% of the global market share

"The rising prevalence of chronic and hereditary diseases in children is driving this market to conduct more studies to improve treatment efficiency. Simultaneously, many clinical trials for COVID-19 vaccinations for children are being done, which is predicted to greatly increase market development. " comments a Future Market Insights analyst.

Key Segments Covered in the Pediatric Clinical Trials Market Report

Pediatric Clinical Trials Market by Phase Type:

  • Phase I Pediatric Clinical Trials
  • Phase II Pediatric Clinical Trials
  • Phase III Pediatric Clinical Trials
  • Phase IV Pediatric Clinical Trials

Pediatric Clinical Trials Market by Study Design:

  • Treatment Studies of Pediatric Clinical Trials
  • Observational Studies of Pediatric Clinical Trials

Pediatric Clinical Trials Market by Therapeutic Areas:

  • Pediatric Clinical Trials for Infectious Diseases
  • Pediatric Clinical Trials for Oncology
  • Pediatric Clinical Trials for Autoimmune/Inflammatory Diseases
  • Pediatric Clinical Trials for Respiratory Disorders
  • Pediatric Clinical Trials for Mental Health Disorders
  • Pediatric Clinical Trials for Other Therapeutic Areas

Pediatric Clinical Trials Market by Region:

  • North American Pediatric Clinical Trials Market
  • Europe Pediatric Clinical Trials Market
  • Asia Pacific Pediatric Clinical Trials Market
  • Middle East & African Pediatric Clinical Trials Market
  • Latin America Pediatric Clinical Trials Market

Get Customization on this Report for Specific Country @ https://www.futuremarketinsights.com/customization-available/rep-gb-15017

Competitive Landscape

The industry analyzed is consolidated due to the sheer existence of a few key competitors in the market, with very few extra participants. Market participants' key strategies included trial initialization, acquisitions, and collaborations.

  • In March 2022, Pfizer initiated a Phase 2/3 study for PAXLOVID tablets, which are specifically designed to treat COVID-19 in young patients. PAXLOVID reduced the risk of hospitalization or death from any cause by 89 percent (within three days of symptom onset) and 88 percent (within five days of appearance of symptoms).
  • In April 2021, Novartis announced plans to initiate SMART, a Phase 3b clinical trial to examine the safety and efficacy of Zolgensma (onasemnogene abeparvovec) in young children with spinal muscular atrophy.

More Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the global pediatric clinical trials market, presenting historical analysis from 2017 to 2021 and forecast statistics for the period of 2022-2032.

The study reveals essential insights on the basis of By Phase (Phase II, IV), By Study Design (Treatment, Observational Studies), By Therapeutic areas(Infectious Diseases, Oncology, Autoimmune/Inflammatory Diseases, Respiratory Disorders, Mental Health Disorders) and Region (North America, South America, Europe, Asia Pacific and Middle East & Africa).

Inquire Before Buying This Research Report @ https://www.futuremarketinsights.com/ask-question/rep-gb-15017

About the Healthcare Division at Future Market Insights

The healthcare team at Future Market Insights offers expert analysis, time efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis on key trends including competitive landscape, profit margin, and research development efforts.

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of the Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favour the market growth in various segments based on Source, Application, Sales Channel and End-Use over the next 8-years.

Contact:

Future Market Insights, Inc
Christiana Corporate,
200 Continental Drive,
Suite 401, Newark,
Delaware - 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
Report: https://www.futuremarketinsights.com/reports/pediatric-clinical-trials-market
Explore all the latest Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs

Logo: https://mma.prnewswire.com/media/1197648/FMI_Logo.jpg

© 2022 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.